Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by Orbimed Advisors LLC

Orbimed Advisors LLC lifted its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 9.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 742,572 shares of the company's stock after buying an additional 66,700 shares during the period. Orbimed Advisors LLC owned approximately 1.17% of Vera Therapeutics worth $31,403,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Vera Therapeutics by 34.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,695 shares of the company's stock worth $1,213,000 after purchasing an additional 7,378 shares in the last quarter. Integral Health Asset Management LLC lifted its stake in Vera Therapeutics by 130.0% in the fourth quarter. Integral Health Asset Management LLC now owns 1,150,000 shares of the company's stock valued at $48,634,000 after buying an additional 650,000 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Vera Therapeutics by 49.9% during the 4th quarter. Janus Henderson Group PLC now owns 21,735 shares of the company's stock worth $919,000 after purchasing an additional 7,235 shares during the period. Ensign Peak Advisors Inc grew its position in Vera Therapeutics by 15.3% during the 4th quarter. Ensign Peak Advisors Inc now owns 13,550 shares of the company's stock worth $573,000 after purchasing an additional 1,800 shares during the last quarter. Finally, Deutsche Bank AG increased its stake in Vera Therapeutics by 5.7% in the fourth quarter. Deutsche Bank AG now owns 810,376 shares of the company's stock valued at $34,271,000 after purchasing an additional 43,832 shares during the period. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Guggenheim raised their price target on Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. JPMorgan Chase & Co. cut their price target on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research note on Tuesday, March 4th. Wolfe Research assumed coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price objective on the stock. Cantor Fitzgerald dropped their price objective on shares of Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Finally, Wedbush cut their price target on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $63.33.

Vera Therapeutics Price Performance

Vera Therapeutics stock traded down $0.08 during mid-day trading on Friday, reaching $21.25. The company had a trading volume of 955,320 shares, compared to its average volume of 780,251. The stock's 50-day simple moving average is $23.63 and its 200-day simple moving average is $34.16. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $51.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The company has a market capitalization of $1.35 billion, a P/E ratio of -8.14 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter in the previous year, the firm earned ($0.56) earnings per share. On average, equities analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.